Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 5/2019

01-05-2019 | Alzheimer's Disease | Original Article

Correlations of serum cystatin C level and gene polymorphism with vascular cognitive impairment after acute cerebral infarction

Authors: Qiong Zeng, Zhihua Huang, Liling Wei, Jingnian Fang, Kun Lin

Published in: Neurological Sciences | Issue 5/2019

Login to get access

Abstract

Background

The aim of this study was to explore the possible correlations of serum cystatin C level and cystatin C gene (CST3) polymorphism with vascular cognitive impairment in patients who had acute cerebral infarction.

Methods

A total of 152 patients with acute cerebral infarction were recruited in this case-control study. Patients were divided into vascular cognitive impairment (VCI) group (n = 71) and cognitive impairment no dementia (CIND) group (n = 81). The serum concentrations of cystatin C were measured with immunoturbidimetric assay while the gene polymorphisms of CST3 were determined by technique polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).

Results

In the VCI group, serum cystatin C level was significantly higher than that in the control group. The frequency of the B allele was found to be higher in the VCI group as compared with that of the CIND group (18.5% vs 7.7%, p = 0.006). In logistic regression analysis, significant associations of VCI with high serum cystatin C level (OR 3.837 (1.176–12.520), p = 0.026) and CST3 B allele (OR 2.038 (1.048–3.963), p = 0.036) were also found.

Conclusions

A high cystatin C level and CST3 B allele confer risks for VCI after acute cerebral infarction. It is probable that measurement of the serum cystatin C level and detection of CST3 gene polymorphism would aid in the early diagnosis of VCI, but further studies are warranted.
Literature
1.
Zeng Q, Lin K, Yao M, Wei L (2015) Significant correlation between cystatin C, cerebral infarction, and potential biomarker for increased risk of stroke. Curr Neurovasc Res 12(1):40–46CrossRefPubMed
2.
Zeng Q, Wei L, Fang J, Li H, Lin K (2017) The correlation between dynamic changes of cystatin C levels and the severity and prognosis of cerebral infarction. J Shantou Univ Med Coll 12(4):206–207
3.
Ghidoni R, Benussi L, Glionna M, Desenzani S, Albertini V, Levy E, Emanuele E, Binetti G (2010) Plasma Cys C and risk of developing Alzheimer’s disease in subjects with mild cognitive impairment. J Alzheimers Dis
4.
Sastre M, Calero M, Pawlik M, Mathews PM, Kumar A, Danilov V, Schmidt SD, Nixon RA, Frangione B, Levy E (2004) Binding of Cys C to Alzheimer’s amyloid beta inhibits in vitro amyloid fibril formation. Neurobiol Aging 25:1033–1043CrossRefPubMed
5.
Levy E, Sastre M, Kumar A, Gallo G, Piccardo P, Ghetti B, Tagliavini F (2001) Codeposition of Cys C with amyloid-beta protein in the brain of Alzheimer disease patients. J Neuropathol Exp Neurol 60:94–104CrossRefPubMed
6.
Deng A, Irizarry MC, Nitsch RM, Growdon JH, Rebeck GW (2001) Elevation of Cys C in susceptible neurons in Alzheimer’s disease. Am J Pathol 159:1061–1068CrossRefPubMedPubMedCentral
7.
Chuo LJ, Sheu WH, Pai MC, Kuo YM (2007) Genotype and plasma concentration of Cys C in patients with lateonset Alzheimer disease. Dement Geriatr Cogn Disord 23:251–257CrossRefPubMed
8.
Kaeser SA, Herzig MC, Coomaraswamy J, Kilger E, Selenica ML, Winkler DT, Staufenbiel M, Levy E, Grubb A, Jucker M (2007) Cys C modulates cerebral beta-amyloidosis. Nat Genet 39:1437–1439CrossRefPubMed
9.
Mi W, Pawlik M, Sastre M, Jung SS, Radvinsky DS, Klein AM, Sommer J, Schmidt SD, Nixon RA, Mathews PM, Levy E (2007) Cys C inhibits amyloid-beta deposition in Alzheimer’s disease mouse models. Nat Genet 39:1440–1442CrossRefPubMed
10.
Ghidoni R, Benussi L, Glionna M, Desenzani S, Albertini V, Levy E, Emanuele E, Binetti G (2010) Plasma cystatin C and risk of developing Alzheimer’s disease in subjects with mild cognitive impairment. J Alzheimers Dis 22(3):985–991CrossRefPubMed
11.
Hu WD, Chen J, Mao CJ, Feng P, Yang YP, Luo WF, Liu CF (2016 Sep) Elevated cystatin C levels are associated with cognitive impairment and progression of Parkinson disease. Cogn Behav Neurol 29(3):144–149CrossRefPubMed
12.
Chen WW, Cheng X, Zhang X, Zhang QS, Sun HQ, Huang WJ, Xie ZY (2015 Aug) The expression features of serum cystatin C and homocysteine of Parkinson’s disease with mild cognitive dysfunction. Eur Rev Med Pharmacol Sci 19(16):2957–2963PubMed
13.
Yaffe K, Kurella-Tamura M, Ackerson L, Hoang TD, Anderson AH, Duckworth M, Go AS, Krousel-Wood M, Kusek JW, Lash JP, Ojo A, Robinson N, Sehgal AR, Sondheimer JH, Steigerwalt S, Townsend RR, the CRIC Study Investigators (2014 Sep) Higher levels of cystatin C are associated with worse cognitive function in older adults with chronic kidney disease: the chronic renal insufficiency cohort cognitive study. J Am Geriatr Soc 62(9):1623–1629CrossRefPubMedPubMedCentral
14.
Yaffe K, Lindquist K, Shlipak MG, Simonsick E, Fried L, Rosano C, Satterfield S, Atkinson H, Windham BG, Kurella-Tamura M, Health ABC Study (2008) Cystatin-C as a marker of cognitive function in elders: findings from the health ABC study. Ann Neurol 63(6):798–802CrossRefPubMedPubMedCentral
15.
Benussi L, Ghidoni R, Steinhoff T, Alberici A, Villa A, Mazzoli F, Nicosia F, Barbiero L, Broglio L, Feudatari E, Signorini S, Finckh U, Nitsch RM, Binetti G (2003) Alzheimer disease-associated Cys C variant undergoes impaired secretion. Neurobiol Dis 13:15–21CrossRefPubMed
16.
American Psychiatric Association (2013) Diagnostic and statistical manual ofMental disorders, 5th edn. American PsychiatricPress, Washington DCCrossRef
17.
Diciotti S, Orsolini S, Salvadori E, Tuscany investigators VMCI (2017) Resting state fMRI regional homogeneity correlates with cognition measures in subcortical vascular cognitive impairment. J Neurol Sci 15(373):1–6CrossRef
18.
Chen KL, Xu Y, Chu AQ, Ding D, Liang XN, Nasreddine ZS, Dong Q, Hong Z, Zhao QH, Guo QH (2016) Validation of the Chinese version of Montreal cognitive assessment basic for screening mild cognitive impairment. J Am Geriatr Soc 64(12):e285–e290CrossRefPubMed
19.
Lin J, Wang X, Dong F, du Y, Shen J, Ding S, Wang L, Ye M, Wang Y, Xia N, Zheng R, Chen H, Xu H (2018) Validation of the Chinese version of the Hamilton Rating Scale for Depression in adults with epilepsy. Epilepsy Behav 89:148–152CrossRefPubMed
20.
Wei Y, Wei YK, Zhu J (2017) Early markers of kidney dysfunction and cognitive impairment among older adults. J Neurol Sci 375:209–214CrossRefPubMed
21.
22.
Ghidoni R, Paterlini A, Albertini V et al (2011) Cystatin C is released in association with exosomes: a new tool of neuronal communication which is unbalanced in Alzheimer’s disease. Neurobiol Aging 32(8):1435–1442CrossRefPubMed
23.
Liang X, Nagai A, Terashima M et al (2011) Cystatin C induces apoptosis and tyrosine hydroxylase gene expression through JNK-dependent pathway in neuronal cells. Neurosci Lett 496(2):100–105CrossRefPubMed
24.
Tizon B, Sahoo S, Yu H et al (2010) Induction of autophagy by cystatin C: a mechanism that protects murine primary cortical neurons and neuronal cell lines. PLoS One 5(3):e9819CrossRefPubMedPubMedCentral
25.
Nagai A, Ryu JK, Terashima M, Tanigawa Y, Wakabayashi K, McLarnon JG, Kobayashi S, Masuda J, Kim SU (2005) Neuronal cell death induced by cystatin C in vivo and in cultured human CNS neurons is inhibited with cathepsin B. Brain Res 1066:120–128CrossRefPubMed
26.
Slinin Y, Peters KW, Ishani A, Yaffe K, Fink HA, Stone KL, Steffes M, Ensrud KE, for the Study of Osteoporotic Fractures (2015) Cystatin C and cognitive impairment 10 years later in older women. J Gerontol A Biol Sci Med Sci 70(6):771–778CrossRefPubMed
27.
28.
Kalman J, Marki-Zay J, Juhasz A, Santha A, Dux L, Janka Z (2000) Serum and cerebrospinal fluid cystatin C levels in vascular and Alzheimer’s dementia. Acta Neurol Scand 101:279–282CrossRefPubMed
29.
Zerovnik E (2009) The emerging role of cystatins in Alzheimer’s disease. Bioessays 31(6):597–599CrossRefPubMed
30.
Levy E (2008) Cys C: a potential target for Alzheimer’s treatment. Expert Rev Neurother 8:687–689CrossRefPubMed
31.
Tobin KA, Holven KB, Retterstøl K (2009) Cys C levels in plasma and peripheral blood mononuclear cells among hyperhomocysteinaemic subjects: effect of treatment with B-vitamins. Br J Nutr 102:1783–1789CrossRefPubMed
32.
Bertram L, Mc Queen MB, Mullin K et al (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the Alz Gene database. Nat Genet 39(1):17–23CrossRef
33.
Benussi L, Ghidoni R, Steinhoff T, Alberici A, Villa A, Mazzoli F, Nicosia F, Barbiero L, Broglio L, Feudatari E, Signorini S, Finckh U, Nitsch RM, Binetti G (2003) Alzheimer disease-associated cystatin C variant undergoes impaired secretion. Neurobiol Dis 13:15–21CrossRefPubMed
34.
Crawford FC, Freeman MJ, Schinka JA, Abdullah LI, Gold M, Hartman R, Krivian K, Morris MD, Richards D, Duara R, Anand R, Mullan MJ (2000) A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer’s disease. Neurology 55:763–768CrossRefPubMed
35.
Maruyama H, Izumi Y, Oda M, Torii T, Morino H, Toji H, Sasaki K, Terasawa H, Nakamura S, Kawakami H (2001) Lack of an association between cystatin C gene polymorphisms in Japanese patients with Alzheimer’s disease. Neurology 57:337–339CrossRefPubMed
36.
Dodel RC, Du Y, Depboylu C et al (2002) A polymorphism in the cystatin C promoter region is not associated with an increased risk of AD. Neurology 58(4):664CrossRefPubMed
37.
Monastero R, Camarda C, Cefalu AB et al (2005) No association between the cystatin C gene polymorphism and Alzheimer’s disease: a case-control study in an Italian population. J Alzheimers Dis 7(4):291–295CrossRefPubMed
38.
Hua Y, Zhao H, Lu X et al (2012) Meta-analysis of the cystatin C (CST3) gene G73A polymorphism and susceptibility to Alzheimer’s disease. Int J Neurosci 122(8):431–438CrossRefPubMed
39.
Strfilberg F, Henning P, Gjertsson I et al (2013) Cysteine proteinase inhibitors regulate human and mouse osteoclastogenesis by interfering with RANK signaling. FASEB J 27(7):2687–2701CrossRef
40.
Cozlea DL, Farcas DM, Nagy A et al (2013) The impact of C reactive protein on global cardiovascular risk on patients with coronary artery disease. Curr Health Sci J 39(4):225–231PubMedPubMedCentral
Metadata
Title
Correlations of serum cystatin C level and gene polymorphism with vascular cognitive impairment after acute cerebral infarction
Authors
Qiong Zeng
Zhihua Huang
Liling Wei
Jingnian Fang
Kun Lin
Publication date
01-05-2019
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 5/2019
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-019-03777-8

Other articles of this Issue 5/2019

Neurological Sciences 5/2019 Go to the issue

Original Article

Mutations in the SPAST gene causing hereditary spastic paraplegia are related to global topological alterations in brain functional networks

Original Article

Withdrawal from acute medication normalises short-term cortical synaptic potentiation in medication overuse headache

Original Article

Efficacy of ultrasound-guided suprascapular nerve block treatment in patients with painful hemiplegic shoulder

Brief Communication

Inflammatory cytokines expression in Wilson’s disease

Brief Communication

Serum orexin-A levels are associated with disease progression and motor impairment in multiple sclerosis

Original Article

Recumbent stepping aerobic exercise in amyotrophic lateral sclerosis: a pilot study